Nevro (NYSE:NVRO) Posts Quarterly Earnings Results, Beats Estimates By $0.15 EPS

Nevro (NYSE:NVRO) released its quarterly earnings data on Tuesday. The medical equipment provider reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.15, Zacks reports. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%.

Nevro Stock Up 0.3 %

NYSE NVRO traded up $0.02 during trading on Tuesday, hitting $5.74. The company’s stock had a trading volume of 627,761 shares, compared to its average volume of 657,297. Nevro has a fifty-two week low of $3.17 and a fifty-two week high of $15.98. The company has a market cap of $214.90 million, a PE ratio of -3.03 and a beta of 0.94. The company has a debt-to-equity ratio of 0.67, a current ratio of 5.02 and a quick ratio of 3.76. The business’s 50 day simple moving average is $4.82 and its 200-day simple moving average is $4.93.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on NVRO shares. Royal Bank of Canada restated a “sector perform” rating and issued a $7.00 price target on shares of Nevro in a report on Tuesday, November 12th. JMP Securities reissued a “market perform” rating on shares of Nevro in a research note on Tuesday, November 12th. Robert W. Baird increased their target price on Nevro from $5.00 to $6.00 and gave the company a “neutral” rating in a research report on Tuesday, November 12th. Citigroup cut their price target on Nevro from $6.00 to $5.00 and set a “neutral” rating on the stock in a report on Wednesday, December 11th. Finally, StockNews.com initiated coverage on Nevro in a research note on Wednesday, February 26th. They set a “hold” rating for the company. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $6.43.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.